oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes | NEJM

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial

20.08

★★★★☆4.8 (126)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

27.12

★★★★★4.9 (98)

NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). ⁣, ⁣, #ACC25 #Cardiology #ClinicalTrials #NEJM

22.03

★★★★★5.0 (157)

Abstract 4367751: Cardiovascular Outcomes of Oral Semaglutide in High Risk Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

21.32

★★★★★4.7 (84)

Projected impact of oral semaglutide on cardiovascular outcomes over

20.33

★★★★★4.9 (203)

An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25

25.76

★★★★★5.0 (176)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

22.20

★★★★★4.8 (132)